Covid-19 roundup: Merck shares molnupiravir with a UN-backed nonprofit; GSK halts Covid-19 research on monoclonal antibody
Merck has agreed to license molnupiravir to UN-backed nonprofit Medicines Patent Pool.
The nonprofit will be working with multiple drugmakers to produce molnupiravir for 105 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.